Fig. 3: Impact of response to ruxolitinib on survival.
From: Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
a Kaplan–Meier estimate for OS probability from begin of ruxolitinib to death of any cause, censored at last follow-up, divided by response at day 28 (CR: complete response, PR: partial response, NR: non-responders). Log-Rank is calculated with landmark analysis, eliminating all patients who did not reach day 28 from the analysis. b Cumulative incidence of non-relapse-related mortality from start of ruxolitinib to death not preceded by relapse/progression of primary cancer; censored at last follow-up; competing event being relapse/progression of primary cancer, divided by response at day 28 (CR: complete response, PR: partial response, NR: non-responders). All patients who did not reach day 28 were eliminated from the landmark analysis.
